东北制药
(000597)
| 流通市值：70.20亿 | | | 总市值：71.31亿 |
| 流通股本：14.07亿 | | | 总股本：14.29亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 6,133,512,515.79 | 4,168,516,475.19 | 1,940,260,731.63 | 8,243,175,021.66 |
| 营业收入 | 6,133,512,515.79 | 4,168,516,475.19 | 1,940,260,731.63 | 8,243,175,021.66 |
| 二、营业总成本 | 5,783,158,351.88 | 3,882,658,259.57 | 1,819,082,084.79 | 7,664,281,359.63 |
| 营业成本 | 4,015,426,869.88 | 2,691,060,711.2 | 1,199,322,797.06 | 4,890,195,587.9 |
| 税金及附加 | 53,452,496.49 | 35,588,690.19 | 17,668,801.54 | 81,746,979.15 |
| 销售费用 | 1,047,384,162.17 | 723,176,074.76 | 386,749,043.1 | 1,809,716,724.85 |
| 管理费用 | 619,708,039.04 | 422,334,492.43 | 204,145,159.73 | 815,553,307.45 |
| 研发费用 | 53,424,342.8 | 35,982,806.73 | 17,035,942.04 | 97,041,920.16 |
| 财务费用 | -6,237,558.5 | -25,484,515.74 | -5,839,658.68 | -29,973,159.88 |
| 其中:利息费用 | 53,028,998.09 | 35,970,635.4 | 17,896,368.05 | 77,391,725.08 |
| 其中:利息收入 | 101,229,361.69 | 77,177,298.43 | 25,685,182.2 | 155,080,614.29 |
| 加:投资收益 | 3,443,648.35 | 2,933,210.38 | 2,273,334.53 | 8,605,948.49 |
| 资产处置收益 | 6,653.37 | 6,653.37 | 6,653.37 | 172,209.96 |
| 资产减值损失(新) | -81,626,706.85 | -66,265,579.63 | -37,669,636.92 | -193,491,641.88 |
| 信用减值损失(新) | -1,673,058.97 | -2,984,933.69 | 257,502.93 | 6,786,090.19 |
| 其他收益 | 65,858,411.31 | 58,754,908.29 | 31,621,808.89 | 97,259,421.64 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 336,363,111.12 | 278,302,474.34 | 117,668,309.64 | 498,225,690.43 |
| 加:营业外收入 | 15,948,218.26 | 3,826,875.39 | 2,363,020.96 | 28,991,702.42 |
| 减:营业外支出 | 3,273,589.14 | 3,370,647.46 | 3,596,740 | 39,045,243.43 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 349,037,740.24 | 278,758,702.27 | 116,434,590.6 | 488,172,149.42 |
| 减:所得税费用 | 128,984,177.81 | 111,863,983.59 | 56,653,590.5 | 112,193,777.5 |
| 六、净利润 | 220,053,562.43 | 166,894,718.68 | 59,781,000.1 | 375,978,371.92 |
| 持续经营净利润 | 220,053,562.43 | 166,894,718.68 | 59,781,000.1 | 375,978,371.92 |
| 归属于母公司股东的净利润 | 207,968,558.91 | 156,809,500.46 | 57,633,861.05 | 358,458,434.72 |
| 少数股东损益 | 12,085,003.52 | 10,085,218.22 | 2,147,139.05 | 17,519,937.2 |
| (一)基本每股收益 | 0.15 | 0.11 | 0.04 | 0.25 |
| (二)稀释每股收益 | 0.15 | 0.11 | 0.04 | 0.25 |
| 八、其他综合收益 | -451,414.36 | 238,720.64 | 66,128.96 | 921,943.04 |
| 归属于母公司股东的其他综合收益 | -453,406.95 | 239,912.99 | 66,473.06 | 919,414.3 |
| 九、综合收益总额 | 219,602,148.07 | 167,133,439.32 | 59,847,129.06 | 376,900,314.96 |
| 归属于母公司股东的综合收益总额 | 207,515,151.96 | 157,049,413.45 | 57,700,334.11 | 359,377,849.02 |
| 归属于少数股东的综合收益总额 | 12,086,996.11 | 10,084,025.87 | 2,146,794.95 | 17,522,465.94 |
| 公告日期 | 2024-10-24 | 2024-08-28 | 2024-04-26 | 2024-03-30 |
| 审计意见(境内) | | | | 标准无保留意见 |